RVU
RYVU THERAPEUTICS
GPW
LISTED
Finance
BETA 2 reports| H1 2026 | Q1 2026 | |
|---|---|---|
| Revenue | 28,939 k PLN | 21.71 m PLN |
| EBITDA | -24,702 k PLN | -10.01 m PLN |
| Net income | -25,705 k PLN | -12.65 m PLN |
We have data for 2 periods. The chart will appear once the next report is published.
Report analyses
2 of 2